

Kent and Medway Cancer Collaborative

Breast Cancer

A High Level Operational Policy

| Publication date | March 2021 |
|----------------------|------------|
| Expected review date | March 2023 |
| Version number | 6.0 |
| Version status | FINAL |

Table of Contents

| 1.0 | INTRODUCTION AND BACKGROUND | . 3 |
|-------------------|--|--------|
| 2.0 | KMCC BREAST CANCER SERVICES | . 3 |
| 3.0 | THE BREAST TSSG | . 4 |
| 4.0 | RESPONSIBILITIES OF THE BREAST TSSG | . 4 |
| 4.1 4.2 4.3 | Function of the TSSG — Termsof Reference Research & Trials Non-Surgical Oncology Group (NOG) | 4 |
| 5.0 | CHILDREN & YOUNG PEOPLE (CYP) / TEENAGE & YOUNG ADULT (TYA) | |
| 5.1 5.2 | Children & Young People (CYP) Teenage & Young Adult (TYA) | 5 5 |
| 6.0 | DATA COLLECTION | . 6 |
| 7.0 | PATHOLOGY | |
| 8.0 | IMAGING | . 7 |
| 9.0 | GLOSSARY | . 7 |
| 10.0 | DOCUMENT ADMINISTRATION | . 8 |

1.0 Introduction and background

The purpose of this document is to provide the Kent & Medway Cancer Alliance Delivery Board, Trusts, Clinical Commissioning Group (CCG) and all Clinicians engaged in the management of Breast Cancers with an overview of the minimum requirements to be addressed in order to achieve Improving Outcomes Guidance (IOG) compliance.

The Breast TSSG will be the KMCA Delivery Boards source of guidance on both the implementation of the Breast Cancer IOG as well as Clinical Protocols and Policies.

An important aim of this document is to provide an overview of the recommendations of the KMCC Breast TSSG on processes to ensure the delivery of clinically safe, evidenced based, clinically effective and IOG compliant Breast Cancer Services. This document does not aim to provide guidance on the clinical aspects of patient management. The clinical guidance recommendations of the KMCC Breast TSSG will be found in the following documents:

- Breast Pathway of Care & Oncological Guidance:
 <u>http://kmcc.nhs.uk/tumour-sites/tumour-site-specific-information/breast-tssg/</u>
 Imaging Guidance:
- Intaging Guidance. http://kmcc.nhs.uk/tumour-sites/sub-groups-or-cross-cutting-groups/diagnostics-group/

2.0 KMCC Breast Cancer Services

- It is agreed that provision of Breast Cancer Services for KMCC is accurately detailed below
- Breast reconstruction services are provided locally by all units along with support from Queen Victoria Hospital
- In East Kent, patients referred for diagnosis at Canterbury will be formally discussed at the QEQM or WHH Breast MDT, depending on post code/patient preference
- Family history patients primary treatment and reconstruction is offered locally or via the Regional Genetics Unit at Guys and St Thomas' NHS Trust

| | Trust | Hospitals providing diagnostic services for Breast cancer | MDTs | Breast Reconstruction Provision |
|---|---|---|------|---------------------------------------|
| Eastern & Coastal Kent Population 781,376 | East Kent Hospitals University NHS Trust | QEQM (Thanet) | QEQM | |
| (Patients flows from Swale are mainly into Medway) | | K&C (Canterbury) | K&C | QVH |
| | | WHH (Ashford) | WHH | |
| Medway & Swale Dartford, Gravesham & Swanley (DGS) Population 647,444 | Medway Foundation Trust Hospital | MFT (Medway & Swale) | MFT | MFT/QVH |
| | Dartford, Gravesham & Swanley NHS Trust | Darent Valley | DVH | DVH/QVH |
| West Kent | | Maidstone | MTW | MTW & QVH |

| Population 463,000 | Maidstone & Tunbridge Wells NHS Trust | Tunbridge-Wells (Pembury) | MTW | MTW & QVH |
|---------------------------|--|------------------------------|-----|-----------|
| | | | | |

The Kent & Medway Breast Cancer TSSG was established in 2000.

- The TSSG is IOG compliant
 - The TSSG has multidisciplinary / multi-professional membership which is drawn from:
 - Each of the Acute Trusts providing Local / Specialist level service
 - **Primary Care**
 - Patient / Users
- The TSSG has a multidisciplinary/multiprofessional membership which is drawn from:
 - Each of the Acute Trusts providing Breast MDT services
 - Primary Care
 - Patient/Users . .

_

| Named Leads for the Breast TSSG are: | | |
|--|---|---|
| Chair | : | Seema Seetharam, Consultant Breast & |
| | | Oncoplastic Surgeon |
| Vice Chair | : | Catherine Harper-Wynne Consultant Medical |
| | | Oncologist |
| KMCC Lead | : | Annette Wiltshire, Service Improvement Facilitator |
| Non Surgical Oncology Group (NOG) Lead | : | Caroline Waters, KMCC Lead Pharmacist/Clinical Lead |
| Research and Trials Lead | | Dr Catherine Harper-Wynne, Consultant Oncologist |
| Users Issues Lead | : | Sue Green, CNS |
| Named Admin Support | : | Karen Glass and Colin Chamberlain, Administrators, KMCC |
| | | |

A full list of current membership is available from the Breast TSSG attendance record – a copy of which is located on the KMCC website: http://kmcc.nhs.uk/tumour-sites/tumour-site-specific-information/breasttssa/

Responsibilities of the Breast TSSG 4.0

Function of the TSSG – Terms of Reference 4.1

A copy of the full Terms of Reference for all TSSGs and the TSSG Chair Job Description is located on the KMCC website: http://kmcc.nhs.uk/tumour-sites/terms-of-reference/

A copy of Breast TSSG Work Plan, and its Annual Report, is located on the KMCC website: http://kmcc.nhs.uk/tumour-sites/tumour-site-specific-information/breast-tssg/

Research & Trials 4.2

It is the responsibility of the TSSG Chair to ensure that the Clinical Trials Report is discussed at the two TSSG meetings held within the 12 month period.

The national initiative to restructure the Research Networks to 15 Local Research Networks has resulted in a reconfigured structure for delivering clinical research across England:

- The three local Cancer Research Networks are now part of the NIHR Clinical Research Network: Kent, Surrey and Sussex
- The new organisation coordinates clinical research and facilitates study set up and delivery, through 30 disease specialties, of which Cancer is one
- The transition to the new organisational structure is ongoing, the Research Portfolio for Kent & Medway is circulated and discussed within each TSSG meeting
- The Research and Trials discussion provides the platform for discussion of cancer clinical studies and act as a resource for information pertaining to those studies

The Breast NOG was formally established in 2008. The NOG work plan is included within the Breast TSSG work plan which is available on the KMCC website:http://kmcc.nhs.uk/tumour-sites/tumour-site-specific-information/breast-tssg/

A copy of the NOG full Terms of Reference is available on the KMCC website: <u>http://kmcc.nhs.uk/tumour-sites/tumour-site-specific-information/breast-tssg/</u>

A copy of the Oncological Treatment of Breast Cancer is located on the KMCC website: <u>http://kmcc.nhs.uk/tumour-sites/tumour-site-specific-information/breast-tssg/</u>

5.0 Children & Young People (CYP) / Teenage & Young Adult (TYA)

5.1 Children & Young People (CYP)

Children and Young People with Breast Cancers will be treated in accordance with principles set out in the CYP IOG.

All Children and Young People up to the age of 18 must be referred to the CYP Principal Treatment Centre which for KMCC is based at the Royal Marsden.

All Young People between 16 and 24 years of age must be offered a referral to the CYP Treatment Centre.

Referral to a CYP Principal Treatment Centre does not necessarily mean that treatment will be undertaken at that centre; shared care management protocols may allow some treatments to be undertaken locally.

5.2 Teenage & Young Adult (TYA)

The main principles in the Teenage & Young Adult guidance are as follows:

- The 16-18 age group should be seen and treated at the TYA Principal Treatment Centre (PTC) and have their management plans discussed by the TYA PTC, although shared care can be arranged as part of the pathway
- Young Adults aged 19-24 years must be given choice where they would like to be treated either:
 In the TYA Principal Treatment Centre
 Or
 - An adult service designated by Commissioners to treat young adults 19 to 24 years
- In both cases all young people must be given access to the services and resources offered by the TYA MDT at the PTC, this may be remotely or through specified clinical services or supportive activities, and each trust will need a mechanism to identify all new TYA patients regardless of which MDT they initially present to.

6.0 Data Collection

Collection of data at each stage of the pathway is the responsibility of the team looking after the patient at that time. The minimum dataset agreed by the TSSG will be a combination of those data items that meet national requirements, and additional items as agreed by the TSSG.

National data requirements will include:

• Cancer Waiting Times monitoring, including Going Further on Cancer Waits. The data items required will be as defined in ISB0147 at the time of referral and/or treatment.

Cancer Waiting Times data will be submitted according to the timetable set out in the National Contract for Acute Services.

• The Cancer Outcomes and Services Dataset. The data items will be as defined in ISB1521, and any subsequent versions, at the time of diagnosis and/or treatment. The requirement will include those fields listed in the "Core" section of the dataset, and any additional tumour site specific sections, as applicable.

Details of the COSD are available from: http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd.aspx

Cancer Registration and Cancer Outcomes and Services (COSD) data will be submitted according to the timetable set out by National Cancer Registration Service.

 Where applicable, teams will also collect additional data items as defined in any corresponding National Clinical Audit Support Programme (NCASP) audit dataset.

Data for NCASP audits will be submitted, where applicable, according to timetables as agreed by the TSSG, and within the overall submission deadlines for each audit.

Submission of data to meet these national requirements will be the responsibility of each individual Trust.

Note that these standards are subject to variation from time to time, and where these requirements change, the data items required to be collected by the team will also change in line with national requirements.

Local data requirements will include any additional data items as agreed by the TSSG. These must be selected to avoid overlap with any existing data items, and where possible must use standard coding as defined in the NHS Data Dictionary.

Where possible and applicable, InfoFlex will be used for the collection and storage of data.

Additional areas of the COSD relating to pathology, radiotherapy, Systemic Anti-Cancer Therapy (SACT) Dataset, diagnostic imaging and basic procedure details will feed into the dataset from other nationally mandated sources. It is the responsibility of each team to ensure that the whole of the relevant dataset is collected, and it is acknowledged that this may come from a variety of sources.

7.0 Pathology

All KMCC reporting Pathologists follow The Royal College of Pathologists Histopathology Reporting on Cancers guidelines – a copy of which is available through the KMCC website:- <u>http://kmcc.nhs.uk/tumour-sites/sub-groups-or-cross-cutting-groups/pathology-group/</u>

All pathologists should participate in the NHSBSP specialist breast EQA scheme. Participation in a general EQA scheme is optional. It is expected that each Trust will monitor this and investigate any deviation from this. Core Cell Path members of the KMCC Breast Teams (and any other Cellular Pathologist providing a Breast Service) will participate in any Breast TSSG agreed cell path related audits.

8.0 Imaging

Imaging guidelines for breast cancer can be located in the TSSG agreed document located on the KMCC website on the following link: <u>http://kmcc.nhs.uk/tumour-sites/sub-groups-or-cross-cutting-groups/diagnostics-group/</u>

9.0 Glossary

Acronyms in common usage throughout KMCC documentation:

| CNB | Cancer Network Board |
|--------|---|
| CYP | Children & Young People (in relation to the IOG) |
| DCCAG | Diagnostic Cross Cutting Advisory Group |
| DOG | Disease Orientated Group (NSSG/TSSG/TWG) |
| DVH | Darent Valley Hospital |
| EK | East Kent |
| EKHUFT | East Kent Hospitals University Foundation Trust |
| HoP | High Level Operational Policy |
| IOSC | Improving Outcomes: A Strategy for Cancer |
| K&C | Kent & Canterbury Hospital, Canterbury, (EKHUFT) |
| KMCA | Kent & Medway Cancer Alliance |
| KMCC | Kent & Medway Cancer Collaborative |
| KMCN | Kent & Medway Cancer Network |
| KMCRN | Kent & Medway Cancer Research Network |
| LSESN | London & South East Sarcoma Network |
| MFT | Medway Foundation Trust |
| MTW | Maidstone & Tunbridge Wells NHS Trust |
| NOG | Non Surgical Oncology Group (Permanent oncologist sub group of the TSSGs |
| | with a specific responsibility for chemo/rad pathways and advice to the TSSG, |
| | KMCC and geographical locations on new drugs) |
| SACT | Systemic Anti-Cancer Therapy |
| PoC | Pathway of Care (KMCC agreed disease site specific clinical guidelines) |
| PTC | Principal Treatment Centre |
| QEQM | Queen Elizabeth the Queen Mother Hospital, Margate (EKHUFT) |
| QoL | Quality of life |
| RAT | Research and Trial Group (Permanent sub-group of the TSSGs with a specific |
| | responsibility for taking forward the clinical trials agenda) |
| RMH | Royal Marsden Hospital |
| TSSG | Tumour Site Specific Group |
| COSD | Cancer Outcomes and Services Dataset |
| QVH | Queen Victoria Foundation Trust Hospital East Grinstead |
| UCLH | University College Hospital London |
| WHH | William Harvey Hospital, Ashford (EKHUFT) |

| WK | West Kent |
|----|-----------|

10.0 Document Administration

| Document Title | Breast Cancer – A High Level Operational Policy | |
|---------------------------|---|--|
| Principle author (s) | D.Hassanally | |
| Co-author(s) | R.Liebmann A.Jackson/I.Vousden/C.Tsatsaklas/H.Devalia/N.Aluwalia | |
| Current version number | 6.0 | |
| Current status | FINAL | |
| Original publication date | March 2021 | |
| Expected review date by | March 2023 | |

| Enquiries: | |
|-----------------------|---------------------------|
| [1] Seema Seetharam | seemaseetharama@nhs.net |
| [2] Annette Wiltshire | annette.wiltshire@nhs.net |

| Revision History | | | |
|-----------------------------|-------------|---|--|
| Date of revision | New Version | Nature of Revision | Confirmation of |
| | Number | | Accuracy by |
| Feb 2009 | 0.1 | Development of Draft OP | A.Jackson |
| June 2009 | 0.2 | General Formatting | C.Tsatsaklas |
| June 2009 | 1.0 | Final | A.Jackson |
| March 2010 | 2.0 | Final 2010 Update | A.Jackson |
| March 2012 | 2.1 | Draft – transfer to new Template – review at DOG meeting | L.Caine |
| June 2012 | 2.2 | Draft – general formatting review | C.Tsatsaklas/S.Stanley |
| September 2012 | 2.3 | Draft – general updates and formatting | C.Tsatsaklas/ C.Waters/ A.Brittle/ B.Mercier/ S.Dicker/ I.Vousden |
| October 2012 | 3.0 | Final - Published | I.Vousden/Breast DOG |
| May 2014 | 3.1 | Draft – updates inc. general admin text/format and weblink updates (remove DOG/KMCN etc, replace with KMCC/TSSG etc) as agreed in 29/04/2014 Breast TSSG | Breast TSSG/ D.Hassanally/ C.Tsatsaklas |
| May 2014 | 4.0 | Final – Breast TSSG 29/04/2014 | Breast TSSG/ D.Hassanally/ C.Tsatsaklas |
| June 2014 | 4.0 | Final/Published – ratified by the Operational & Quality Group (25/6/14) | Operational & Quality Group |
| June 2016 | 4.1 | Amendments to named leads and provision of services. To be reviewed at the next TSSG | N.Aluwalia |
| July 2016 | 4.2 | Updates added following TSSG meeting. Sent for comments to H.Devalia | N.Aluwalia |
| Aug 2016 | 4.3 | Updates added as per group comments | N.Aluwalia/ K.Palmer |
| September 2016 | 5.0 | Final version ratified by the O&Q Group | N.Aluwalia |
| February 2020 March 2021 | 5.1 | Draft updates with new Chair & Vice Chair, review of correct weblinks & document | S. Seetharam / A. Wiltshire |
| September 2021 | 6.0 | Final version ratified following TSSG meeting | S. Seetharam / A. Wiltshire |